Welcome to LookChem.com Sign In|Join Free

CAS

  • or

72978-22-4

Post Buying Request

72978-22-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

72978-22-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 72978-22-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,2,9,7 and 8 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 72978-22:
(7*7)+(6*2)+(5*9)+(4*7)+(3*8)+(2*2)+(1*2)=164
164 % 10 = 4
So 72978-22-4 is a valid CAS Registry Number.

72978-22-4Relevant articles and documents

Stereoselective Synthesis of New (2 S,3 R)-3-Carboxyphenyl)pyrrolidine-2-carboxylic Acid Analogues Utilizing a C(sp3)-H Activation Strategy and Structure-Activity Relationship Studies at the Ionotropic Glutamate Receptors

Bunch, Lennart,Hansen, Jacob C.,Hansen, Kasper B.,Iliadis, Stylianos,Kayser, Silke,Krogsgaard-Larsen, Niels,Larsen, Younes,Moroz, Aleksandra,Nielsen, Birgitte,Pickering, Darryl S.,Staudt, Markus,Syrenne, Jed T.,Temperini, Piero,Yi, Feng

, (2020/03/10)

Competitive antagonists for ionotropic glutamate receptors (iGluRs) are highly valuable tool compounds for studying health and disease states in the central nervous system. However, only few subtype selective tool compounds are available and the discovery of antagonists with novel iGluR subtype selectivity profiles remains a profound challenge. In this paper, we report an elaborate structure-activity relationship (SAR) study of the parental scaffold 2,3-trans-3-carboxy-3-phenyl-proline by the synthesis of 40 new analogues. Three synthetic strategies were employed with two new strategies of which one being a highly efficient and fully enantioselective strategy based on C(sp3)-H activation methodology. The SAR study led to the conclusion that selectivity for the NMDA receptors was a general trend when adding substituents in the 5′-position. Selective NMDA receptor antagonists were obtained with high potency (IC50 values as low as 200 nM) and 3-34-fold preference for GluN1/GluN2A over GluN1/GluN2B-D NMDA receptors.

THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF

-

Page/Page column 262, (2016/01/25)

The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Dehydrooligopeptides. XII. Convenient synthesis of various kinds of N-benzyloxycarbonyl-α-dehydroamino acid methyl esters

Shin,Takahashi,Yonezawa

, p. 2020 - 2023 (2007/10/02)

-

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 72978-22-4